Geron will find a partner for its human embryonic stem cell (hESC) therapeutic programs, a more than two-to-one majority of voters on GEN’s poll agreed. With 63.1% saying yes, 31.5% believe the firm will not find a partner and 5.4% were undecided. Geron, a pioneer in stem cell research founded in 1990, announced on November 14 that it was halting its stem cell therapeutic programs and is seeking partners for these assets. At the time, Geron had been developing differentiated hESCs, with its lead product in Phase I for spinal cord injury. Advanced Cell Technology (ACT) remains the only company left with ongoing clinical trials involving hESCs.